Korean Circ J.  2024 Aug;54(8):466-467. 10.4070/kcj.2024.0182.

Should We Leave Something There?

• Lee CH
• Kim W

• KMID: 2558537
• DOI: http://doi.org/10.4070/kcj.2024.0182

Reference

1. Ko YG, Ahn CM, Min PK, et al. Baseline characteristics of a retrospective patient cohort in the Korean vascular intervention society endovascular therapy in lower limb artery diseases (K-VIS ELLA) registry. Korean Circ J. 2017; 47:469–476. PMID: 28765738.

2. Cha JJ, Lee JH, Ko YG, et al. Clinical outcomes of atherectomy plus drug-coated balloon versus drug-coated balloon alone in the treatment of femoropopliteal artery disease. Korean Circ J. 2022; 52:123–133. PMID: 34877824.

3. Kim S. Improving the outcomes of complex lesions of the femoropopliteal artery using atherectomy and drug coated balloon. Korean Circ J. 2022; 52:134–135. PMID: 35128850.

4. Park JI, Ko YG, Lee SJ, et al. Clinical outcomes after drug-coated balloon treatment in popliteal artery disease: K-POP registry 12-month results. Korean Circ J. 2024; 54:454–465. PMID: 38767445.

5. Torsello G, Stavroulakis K, Brodmann M, et al. Three-year sustained clinical efficacy of drug-coated balloon angioplasty in a real-world femoropopliteal cohort. J Endovasc Ther. 2020; 27:693–705. PMID: 32583749.

6. Wu X, Peng Z, Qin J, Yang X, Lu X, Ye K. Outcomes of drug-coated balloon angioplasty for isolated chronic occlusion of the popliteal artery: a retrospective single-institution study. J Vasc Interv Radiol. 2021; 32:593–601. PMID: 33531180.

7. Stavroulakis K, Schwindt A, Torsello G, et al. Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for isolated popliteal artery lesions. J Endovasc Ther. 2017; 24:181–188. PMID: 28008792.